Oncology Today with Dr Neil Love

Epizody

• 
  Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal 02.10.2026 52min

  Featuring an interview with Dr Neeraj Agarwal, including the following topics:Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)Managing treatment-related adverse events from capivasertib (20:08)Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)CME information and select publications
• 
  HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer 01.10.2026 23min

  Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00)Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29)CME information and select publications
• 
  Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 01.10.2026 50min

  Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)CME information and select publications
• 
  Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 01.10.2026 51min

  Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)Ovarian Cancer (2:22)Endometrial Cancer (37:48)CME information and select publications
• 
  For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon 30.09.2026 58min

  Featuring an interview with Dr Alexander E Drilon, including the following topics:Overview of targetable biomarkers in lung cancer (0:00)Biomarker testing for genomic alterations in lung cancer (5:24)Overview of ROS1 alterations in lung cancer (13:44)Efficacy data with ROS1 inhibitors for lung cancer (17:02)Safety data with ROS1 inhibitors for lung cancer (21:15)Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)NCPD information and select publications
• 
  Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo 29.09.2026 48min

  Featuring an interview with Professor Nicoletta Colombo, including the following topics:Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00)Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31)Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02)Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25)Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43)Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46)CME information and select publications
• 
  Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 28.09.2026 50min

  Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)Management of HER2-Positive Gastroesophageal Cancer (25:11)Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.CME information and select publications
• 
  Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 28.09.2026 54min

  Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Therapy (2:48)Relapsed/Refractory Disease (39:30)CME information and select publications
• 
  Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress 25.09.2026 1h 28min

  Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:Introduction (0:00)Trials in Progress (1:12)Chronic Lymphocytic Leukemia (7:09)Diffuse Large B-Cell Lymphoma (32:35)Mantle Cell Lymphoma (58:25)Follicular Lymphoma (1:14:49)CME information and select publications
• 
  HER2-Positive Gynecologic Cancers — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer 24.09.2026 9min

  Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic:Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A LedermannCME information and select publications
• 
  Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov 23.09.2026 49min

  Featuring an interview with Dr Douglas W Sborov, including the following topics:DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)Prevention and management of ophthalmic events related to treatment with belamaf (21:27)Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)CME information and select publications
• 
  Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 2 with Dr David W Cescon 22.09.2026 23min

  Featuring perspectives from Dr David W Cescon, including the following topics:Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)CNS activity of TROP2-directed antibody-drug conjugates (5:36)Autoimmune considerations with immunotherapy (10:09)Treatment of oligoprogressive advanced breast cancer (17:31)CME information and select publications
• 
  Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon 21.09.2026 29min

  Featuring perspectives from Dr David W Cescon, including the following topics:First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)Adverse events (19:39)CME information and select publications
• 
  Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting 17.09.2026 58min

  Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics:Introduction (0:00)Preventing Ovarian Cancer (1:04)Endometrial Cancer (5:27)Ovarian Cancer (25:36)Cervical Cancer (54:04)CME information and select publications
• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 8 16.09.2026 25min

  Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)CME information and select publications
• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 7 16.09.2026 36min

  Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)CME information and select publications
• 
  Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting 15.09.2026 1h 29min

  Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:Introduction (0:00)Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)HER2-Positive Breast Cancer — Dr Bardia (42:46)Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)CME information and select publications
• 
  Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 14.09.2026 26min

  Featuring perspectives from Dr Rachel N Grisham, including the following topics:Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)CME information and select publications
• 
  Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1 13.09.2026 28min

  Featuring perspectives from Dr Rachel N Grisham, including the following topics:Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)Current and future role of avutometinib with defactinib for LGSOC (19:23)A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)CME information and select publications
• 
  Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus 11.09.2026 59min

  Featuring an interview with Prof Andreas Hochhaus, including the following topics:Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)Potential mechanisms of adverse events documented with TKIs (10:23)Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)Comparative efficacy of asciminib and other agents used to treat CML (40:01)Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)Practical care strategies for CML patients; future developments (52:32)CME information and select publications